Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study testing the effects of neoadjuvant therapy with the
aromatase inhibitor letrozole in post-menopausal women with Stage I-III ER+, HER2- breast
cancer. Eligible subjects will be treated with letrozole therapy for 4 to 12 weeks prior to
surgical resection of the tumor. Tumor specimens obtained at baseline (diagnostic biopsy) and
at surgery (surgical specimen) will be compared using molecular analyses. A subset of
subjects will be asked to provide an optional research tumor biopsy prior to treatment for
molecular analysis.